A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  New England Journal of Medicine

• Publication date

  2015-07-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMoa1501646PMID 26154787
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up

  2015cited by this paper
• Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis

  2015cited by this paper
• Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled,

  2014cited by this paper
• Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.

  2014cited by this paper
• Long‐term safety of ustekinumab in patients with moderate‐to‐severe psoriasis: final results from 5 years of follow‐up

  2013cited by this paper
• Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis treated for up to 5 years in the PHOENIX 1 study

  2013cited by this paper
• Efficacy and safety of secukinumab in the treatment of moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled phase II dose‐ranging study

  2013cited by this paper
• Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

  2013cited by this paper
• Autocrine IL-17A–IL-17RC neutrophil activation in fungal infections is regulated by IL-6, IL-23, RORγt and Dectin-2

  2013cited by this paper
• Targeting the Th17 pathway in psoriasis

  2012cited by this paper
• IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis.

  2012cited by this paper
• Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.

  2012cited by this paper
• Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.

  2012cited by this paper
• Secukinumab induction and maintenance therapy in moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled, phase II regimen‐finding study

  2012cited by this paper
• Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis

  2011cited by this paper
• Childhood psoriasis treatment: evidence published over the last 5 years.

  2011cited by this paper
• Discovery and mechanism of ustekinumab

  2011cited by this paper
• Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.

  2010cited by this paper
• The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17–producing effector T helper cells in vivo

  2009cited by this paper
• Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis.

  2009cited by this paper
• IL-23 Promotes Maintenance but Not Commitment to the Th17 Lineage1

  2008cited by this paper
• Activation of keratinocyte protein kinase C zeta in psoriasis plaques.

  2008influential reference
• Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).

  2008cited by this paper
• Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).

  2008cited by this paper
• Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

  2008cited by this paper
• Pathogenesis and therapy of psoriasis

  2007cited by this paper
• Pathogenesis and clinical features of psoriasis.

  2007influential reference
• Psoriasis causes as much disability as other major medical diseases.

  1999cited by this paper
• Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells

  1993cited by this paper

• The molecular mechanism of the adverse effects of the biological and small molecular drugs in the therapy of inflammatory skin diseases – psoriasis and atopic dermatitis

  2026cites this paper
• Inflame and restrain - the paradoxical roles of IL-12 and IL-23 in immunity.

  2026cites this paper
• Biologics for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-analysis

  2025cites this paper
• Is psoriatic arthritis a dissemination of cutaneous psoriatic TRM cells? Role of tissue-resident memory T cells (TRM) in psoriatic disease.

  2025cites this paper
• Comparative Efficacy and Safety of Biologic Therapies for Moderate-to-Severe Psoriasis

  2025cites this paper
• Interleukin-23p19 inhibitors for the treatment of moderate-to-severe psoriasis: an expert opinion of real-world evidence studies in Europe

  2025cites this paper
• Systematic review of comparative studies on emerging psoriasis treatments: comparing biologics with biologics, small molecule inhibitors with small molecule inhibitors, and biologics with small molecule inhibitors

  2025cites this paper
• The Role of IL-12 Family Cytokines in the Pathogenesis of Periodontal Disease: A Therapeutic Approach

  2025cites this paper
• Biologic Therapies and Major Cardiovascular Events in Psoriasis: Updated Systematic Review and Meta-analysis

  2025cites this paper
• A systematic review and network meta-analysis comparing the efficacy and safety of deucravacitinib versus selected treatments for moderate to severe plaque psoriasis

  2025cites this paper
• Landscape of anti-IL-23 therapy in inflammatory bowel disease: recent advances

  2025cites this paper
• Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

  2025cites this paper
• Structure and assembly of the human IL-12 signaling complex.

  2024cites this paper
• Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence.

  2024cites this paper
• A Successful Switch From Ustekinumab to an Extended Dosing Interval of Guselkumab Without Induction in a Patient With Psoriasis Vulgaris

  2024cites this paper
• IL-23 inhibition for chronic inflammatory disease.

  2024cites this paper
• Risk of tuberculosis disease in patients receiving TNF-α antagonist therapy: A meta-analysis of randomized controlled trials

  2024cites this paper
• Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review.

  2024cites this paper
• Serious adverse events associated with systemic treatments for psoriasis: a network meta-analysis of observational studies and randomized controlled trials

  2024cites this paper
• Preliminary Investigation and Therapeutic Efficacy Determination of a Novel Anti-IL-17A Antibody, Indikizumab

  2024cites this paper
• Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial (COMFORT‐1)

  2024cites this paper
• Transportability of aggregate trial results to an external environment in causally interpretable meta-analysis

  2024cites this paper
• IL-17 and IL-23 Inhibitors Have the Fastest Time to Meaningful Clinical Response for Plaque Psoriasis: A Network Meta-Analysis

  2024cites this paper
• Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy

  2024cites this paper
• FPR1 contributes to epidermal barrier dysfunction-induced skin inflammation through NLRC4-dependent keratinocyte activation.

  2023cites this paper
• Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis

  2023cites this paper
• Biologics for Reducing Cardiovascular Risk in Psoriasis Patients

  2023cites this paper
• Novel Biotherapeutics Targeting Biomolecular and Cellular Approaches in Diabetic Wound Healing

  2023cites this paper
• Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis

  2023cites this paper
• Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?—Insights from an international population‐based study

  2023cites this paper
• Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease

  2023cites this paper
• Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

  2023cites this paper
• Impact of targeted therapies on the risk of cardiovascular events in patients with psoriasis and psoriatic arthritis: A systematic review and aggregate data meta‐analysis of randomized controlled trials

  2023cites this paper
• Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data

  2023influential citation
• The evolving landscape of biologic therapies for atopic dermatitis: Present and future perspective

  2023cites this paper
• Comparative short-term risks of infection and serious infection in patients receiving biologic and small-molecule therapies for psoriasis and psoriatic arthritis: a systemic review and network meta-analysis of randomized controlled trials

  2023cites this paper
• Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review.

  2023cites this paper
• Further evidence for the long-term safety of guselkumab.

  2023cites this paper
• Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study.

  2023cites this paper
• Study the Serum Levels of IL-17, IL-23, TLR-4, and TLR-7 Role in Immunopathogenesis in Patients with Moderate and Severe Psoriasis

  2023cites this paper
• A systematic review investigating at what proportion clinical images are shared in prospective randomized controlled trials involving patients with psoriasis and biological agents

  2023cites this paper
• Safety of Guselkumab Treatment for up to 5 Years in Patients With Moderate-to-Severe Psoriasis: Pooled Analyses Across Seven Clinical Trials With Greater Than 8600 Patient-Years of Exposure.

  2023cites this paper
• Developing Novel Molecular Targeted Therapeutics for Topical Treatment of Psoriasis

  2023cites this paper
• Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis

  2023influential citation
• Comparative effectiveness of adalimumab versus ustekinumab in the treatment of severe chronic plaque psoriasis: The results based on data from the program “treatment of moderate and severe forms of plaque psoriasis (B.47)” of the National Health Fund in Poland

  2022cites this paper
• Population pharmacokinetics analysis of guselkumab in healthy subjects and patients with psoriatic arthritis, plaque psoriasis and palmoplantar pustulosis

  2022cites this paper
• Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis

  2022influential citation
• Anti‐drug antibodies of IL‐23 inhibitors for psoriasis: a systematic review

  2022cites this paper
• Current advances in biological therapy of psoriasis: efficacy of guselkumab in real clinical practice

  2022cites this paper
• Orchestrated Cytokines Mediated by Biologics in Psoriasis and Its Mechanisms of Action

  2022cites this paper
• Biological Treatments for Pediatric Psoriasis: State of the Art and Future Perspectives

  2022cites this paper
• Blockade of IL-23: What is in the Pipeline?

  2022cites this paper
• A real‐life experience as a proof of Guselkumab effectiveness and safety in patients with moderate to severe psoriasis

  2022cites this paper
• English version of Japanese guidance for use of biologics for psoriasis (the 2022 version)

  2022cites this paper
• Efficacy of guselkumab compared with adalimumab for psoriasis: a meta-analysis of randomized controlled studies

  2022influential citation
• Understanding efficacy-safety balance of biologics in moderate-to-severe pediatric psoriasis

  2022cites this paper
• Staphylococcus aureus skin colonization promotes SLE-like autoimmune inflammation via neutrophil activation and the IL-23/IL-17 axis

  2022cites this paper
• Risk of Candida Infection and Serious Infections in Patients with Moderate-to-Severe Psoriasis Receiving Biologics: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2022cites this paper
• Super‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance

  2022cites this paper
• Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

  2022cites this paper
• Infection risk in psoriatic patients receiving tumour necrosis factor inhibitors: a 20‐year systematic review and meta‐analysis of randomized controlled trials

  2022cites this paper
• Racial and ethnic diversity of US participants in clinical trials for acne, atopic dermatitis, and psoriasis: a comprehensive review

  2022cites this paper
• Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis

  2021cites this paper
• Major Role of the IL17/23 Axis in Psoriasis Supports the Development of New Targeted Therapies

  2021cites this paper
• Systemic Treatments for Adult Patients with Moderate-to-Severe Psoriasis: Consensus Statements for the United Arab Emirates

  2021cites this paper
• Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis

  2021influential citation
• Phosphodiesterase-4 Inhibition Reduces Cutaneous Inflammation and IL-1β Expression in a Psoriasiform Mouse Model but Does Not Inhibit Inflammasome Activation

  2021cites this paper
• Non-invasive tape-stripping with high-resolution RNA profiling effectively captures a pre-inflammatory state in nonlesional psoriatic skin.

  2021cites this paper
• The Antidiabetic Agent Metformin Inhibits IL-23 Production in Murine Bone-Marrow-Derived Dendritic Cells

  2021cites this paper
• Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis

  2021cites this paper
• A non-clinical comparative study of IL-23 antibodies in psoriasis

  2021cites this paper
• Recent Updates in Juvenile Spondyloarthritis.

  2021cites this paper
• CCID_A_235242 55..63

  2021cites this paper
• Deciphering the mechanism of Fang-Ji-Di-Huang-Decoction in ameliorating psoriasis-like skin inflammation via the inhibition of IL-23/Th17 cell axis.

  2021cites this paper
• Axonal sensorimotor polyneuropathy after starting guselkumab

  2021cites this paper
• Vergleich der Wirksamkeit und Sicherheit von Biologika bei mittelstark bis stark ausgeprägter Plaque‐Psoriasis: Metaanalyse multipler Therapien

  2021cites this paper
• Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method

  2021cites this paper
• Comparative Safety and Benefit-Risk Profile of Biologics and Oral Treatments for Moderate-to-Severe Plaque Psoriasis: a Network Meta-Analysis of Clinical Trial Data.

  2021cites this paper
• Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis

  2021influential citation
• Advances in Psoriasis: A Multisystemic Guide

  2021influential citation
• Role of IL-23 neutralization in psoriasis: insights from a mechanistic PK/PD model and meta-analysis of clinical data

  2021cites this paper
• Adverse Events Associated With Anti-IL-23 Agents: Clinical Evidence and Possible Mechanisms

  2021cites this paper
• Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

  2021cites this paper
• Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis

  2021cites this paper
• Interleukin 23 Inhibitors

  2021cites this paper
• Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics

  2021cites this paper
• The Role of Th17-Related Cytokines in Atopic Dermatitis

  2020influential citation
• Treatment of psoriasis: JAK inhibitors and biologics for the Interleukin-23/Th17 axis.

  2020cites this paper
• Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year

  2020cites this paper
• Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis

  2020cites this paper
• Japanese guidance for use of biologics for psoriasis (the 2019 version)

  2020cites this paper
• Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

  2020cites this paper
• Guselkumab in the treatment of patients with plaque psoriasis of moderate and severe severity: Efficacy and safety of interleukin-23 blockade

  2020influential citation
• Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor, PF 06700841, Reveal Reduction of Skin Inflammation in Plaque Psoriasis: TYK2/JAK1 inhibitor in plaque psoriasis.

  2020cites this paper
• Efficacy and safety of guselkumab for the treatment of patients with moderate-to-severe plaque psoriasis: A meta- analysis of randomized clinical trials

  2020cites this paper
• Guselkumab in the treatment of moderate-to-severe plaque psoriasis.

  2020cites this paper
• Management of Plaque Psoriasis: A Review and Comparison of IL-23 Inhibitors

  2020cites this paper
• Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review

  2020cites this paper
• Guselkumab

  2020cites this paper
• Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple‐treatments meta‐analysis

  2020cites this paper